Papillary Renal Cell Carcinoma — Trials

Papillary Renal Cell Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

32 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 14
Recruiting: 5
Ph III recruiting: 0
Growth YoY: —
Industry share: 21%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (3)

clinicaltrialsPublishedShowing 1–2 of 2 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02837991	A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma	terminated	Phase 1	16	Celldex TherapeuticsINDUSTRY	1	Jun 4, 2020	clinicaltrials
NCT00098618	Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic Kidney Cancer	terminated	Phase 2	40	National Cancer Institute (NCI)NIH	1	Jul 2, 2013	clinicaltrials